Nirmatrelvir/Ritonavir May Reduce Risk Of Long COVID, Large Study Suggests

November 08, 2022

The Washington Post (11/7, Sellers) reports patients with COVID-19 “who were treated with” nirmatrelvir/ritonavir (Paxlovid), “the oral antiviral that has proved highly effective at preventing hospitalization and death among elderly and at-risk people, ap...